News

Look back: the first In-vitro 2D and 3D Neuronal Networks Summit (MaxWell Biosystems User Meeting) 

On April 22nd and 23rd, we hosted the first In-vitro 2D and 3D neuronal Networks Summit (MaxWell Biosystems User Meeting) and were very excited about the tremendously successful outcome, with over 700 registrants from 49 countries!   First Day: Scientific Talks and Discussions Open for All The first day of the meeting was open to everybody. We had very interesting talks from seven invited speakers, who spoke about their work involving iPSC-derived neurons, brain organoids, and also high-density microelectrode array (HD-MEA)…

Read More

HD-MEAs play a role in the functional characterization of human iPSC-derived dopaminergic neurons

Maria Sundberg from the Boston Children’s Hospital, Harvard Medical School, and colleagues, recently reported in Nature Communications a study on the reciprocal copy number variations (CNVs) of 16p11.2 gene region, associated with a wide spectrum of neuropsychiatric and neurodevelopmental disorders. For the functional analysis of the developing iPSC-derived dopaminergic (DA) neuron network, complementary-metal-oxide-semiconductor (CMOS)-based high-density microelectrode arrays (HD-MEAs), MaxOne System by MaxWell Biosystems was extensively used. 16p.11.2 Reciprocal copy number variations (CNVs) in neuropsychiatric disorders 16p.11.2 CNVs have been implicated in…

Read More

Observing the activity of human-derived neurons in health and in disease

The combination of two technologies—induced pluripotent stem cells and high-density microelectrode arrays—offers an unprecedented platform to study human brain activity in detail outside the body.    Back in 2006, Prof. Yamanaka and colleagues revealed a technique to reprogram adult skin cells into embryonic-like cells called induced pluripotent stem cells or iPSCs. This Nobel Prize winning technology enables access to human neurons derived from adult blood or skin cells in a high-throughput manner, thus opening up the possibilities to study neurological…

Read More

MaxWell Biosystems Completes CHF 4 million Series A Financing Round

Zurich, Switzerland, 16 December 2020 – MaxWell Biosystems AG, a spin-off from ETH Zürich founded in 2016 announced today the closing of a CHF 4 million Series A financing round to further industrialize and scale-up the production of their consumables, so called multiwell high-density microelectrode array (HD-MEA) plates. Such scale-up will enable the customers of MaxWell Biosystems in the pharmaceutical industry to run functional drug screenings at a higher throughput and ultimately contribute to accelerate the development of drugs targeting…

Read More

MaxWell Biosystems introduces its new headquarters in Zurich

Since 2016, MaxWell Biosystems was located in the same premises as the Department of Biosystems Science and Engineering at ETH Zurich in Basel. With the growing team and the need for our own headquarters, we searched and found our new home in Zurich. With the dynamic startup ecosystem, world-class universities, and of course the beautiful lake and mountains, Zurich is a great place for MxW. It is here where we will continue to grow the team, develop new products, and connect to…

Read More
Contacts










Albisriederstrasse 253
8047 Zurich, Switzerland

+41 44 244 24 24

Schedule a call

info@mxwbio.com

Subscribe to our Newsletter